Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 48.27M | 59.93M | 76.41M | 107.03M | 87.89M | 45.16M |
Gross Profit | 8.52M | 13.64M | 27.19M | 28.69M | 25.99M | 17.25M |
EBITDA | -36.03M | -37.42M | -29.04M | -4.38M | -1.47M | -31.69M |
Net Income | -42.51M | -40.19M | -42.05M | -12.21M | -7.74M | -36.68M |
Balance Sheet | ||||||
Total Assets | 187.16M | 192.32M | 221.19M | 225.96M | 217.82M | 196.83M |
Cash, Cash Equivalents and Short-Term Investments | 2.41M | 4.01M | 11.48M | 8.54M | 4.59M | 10.24M |
Total Debt | 5.54M | 5.66M | 6.04M | 18.47M | 5.36M | 3.13M |
Total Liabilities | 135.74M | 132.56M | 127.23M | 140.82M | 117.83M | 96.10M |
Stockholders Equity | 43.94M | 52.04M | 86.33M | 79.58M | 95.04M | 96.97M |
Cash Flow | ||||||
Free Cash Flow | -3.67M | -7.03M | -9.59M | 31.00M | -10.90M | -22.19M |
Operating Cash Flow | -3.05M | -6.40M | -8.22M | 31.80M | -9.06M | -21.76M |
Investing Cash Flow | 190.00K | -301.00K | -5.40M | -35.29M | -1.84M | -1.70M |
Financing Cash Flow | 1.46M | -1.24M | 27.66M | 12.96M | 2.63M | 3.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | AU$2.47B | 4.40 | -64.25% | 2.83% | 36.51% | 13.14% | |
42 Neutral | HK$147.49M | ― | -71.31% | ― | -35.16% | -37.27% | |
$8.32B | 9.37 | 6.08% | 2.95% | ― | ― | ||
$7.35B | 6.88 | 9.19% | 4.34% | ― | ― | ||
78 Outperform | HK$3.24B | 10.59 | 7.40% | 4.59% | 0.67% | -1.75% | |
45 Neutral | HK$682.04M | ― | -31.49% | ― | -7.28% | -46.18% | |
HK$761.40M | 13.18 | 8.78% | 6.93% | ― | ― |
China Health Group Limited has announced a trading halt on its shares on the Hong Kong Stock Exchange, effective from May 2, 2025. This suspension is due to an upcoming announcement related to the Hong Kong Code on Takeovers and Mergers, which contains inside information about the company. The halt indicates potential significant changes or developments within the company that could impact its operations and market positioning.
China Health Group Limited has announced a change in its Hong Kong Branch Share Registrar and Transfer Office, effective from March 31, 2025. The new registrar will be Tricor Investor Services Limited, which will handle all share transfer applications and uncollected share certificates from that date. This change is part of the company’s operational adjustments and may impact stakeholders involved in share transactions.
China Health Group Limited announced a major transaction involving the acquisition of a 51% equity interest in a target company and the provision of loans to this company. The acquisition was initially misclassified as a discloseable transaction due to an oversight regarding the aggregation rules under the Listing Rules. This oversight led to the failure to disclose the Initial Loan provided to the target company before the acquisition agreement. The company has since provided additional loans, and the combined transactions now qualify as a major transaction, necessitating further reporting and shareholder approval.
China Health Group Limited has announced a further extension of the long stop date for its acquisition of ProteinT (Tianjin) Diagnostic, Co., Ltd., moving it from 28 February 2025 to 30 June 2025. This extension is due to the additional time required to prepare the necessary circular for shareholders, which has also delayed its dispatch to a new deadline of 30 June 2025. The extension suggests ongoing complexities in finalizing the acquisition, potentially impacting the company’s strategic plans and stakeholder expectations.